ICU: SeaStar Medical EV/EBITDA Multiple
SeaStar Medical Holding (ICU) is developing a blood purification system utilizing selective cytokine filtration. This price chart, where the EV/EBITDA ratio stands at 0.00, illustrates a model driven by consistent demand for replacement cartridges. Growth depends on FDA approval and the results of trials across various age groups. Furthermore, the humanitarian profile of these developments ensures business stability, completely eliminating the risks of sanctions or trade restrictions.
Summary analytical data breakdowns for SeaStar Medical (ICU)
- stock price and consensus target price:
- market capitalization information:
- issuer book value statistics:
- company liabilities and liquidity data:
Debt to Equity SeaStar Medical Holding|ICU - Long-Term Debt to Equity Ratio|Short-Term Debt to Capital seastarmedical.com|ICU - Company Cumulative Debt|Debts to Book Capitalization SeaStar Medical|ICU - Company Long-Term Indebtedness|Company Short-Term Debts SeaStar Medical|Quick Ratio seastarmedical.com
- financial results and valuation multiples details:
ICU - Net Income|Projected Future Earnings SeaStar Medical Holding|ICU - P/E Multiple|Future Price to Earnings SeaStar Medical|ICU - Price/Earnings to Growth Ratio|Enterprise Value to EBITDA Ratio SeaStar Medical Holding Corp|ICU - Income before deduction of interest, taxes and amortization|Net earnings per share (EPS TTM) SeaStar Medical|ICU - Net earnings per one share for the last twelve months|Year-over-year earnings per share growth for the last twelve months seastarmedical.com|ICU - Net earnings per share change in current year|Expected earnings per share growth for next year SeaStar Medical Holding
- sales and revenue data:
Initial company analysis:SeaStar Medical ICU
For SeaStar Medical Holding, a manufacturer of blood purification systems, the historical EV/EBITDA trajectory reflects the business's real value while accounting for its debt load. This metric compares the total enterprise value with its operating profit before taxes, allowing investors to filter out speculative noise and determine the extent of the asset's overvaluation based on the ability of the medical technologies to generate cash flow.
Competitor analysis for SeaStar Medical Holding
Dexcom CGM - Enterprise Value to EBITDA Ratio|Enterprise Value to Operating Income Before Depreciation Ratio PEN (Penumbra, Inc.)|NOVT: Enterprise Value to EBITDA Ratio|Total Company Value to Operating Income Before Depreciation Ratio Haemonetics HAE|INSP: EV/EBITDA Multiple|PRCT - Total Company Value to Operating Income Before Depreciation Ratio|CNMD (conmed.com) - EV/EBITDA Multiple|Enterprise Value to EBITDA Ratio Pulse Biosciences (PLSE)|Enterprise Value to EBITDA Ratio INMD (InMode)|Enterprise Value to EBITDA Ratio Picard Medical PMI|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Surmodics Inc. SRDX|SENS - Enterprise Value to EBITDA Ratio|NeuroPace Inc - EV/EBITDA Multiple|Company Value to EBITDA tactilemedical.com|SNWV: EV/EBITDA Multiple|Enterprise Value to EBITDA Ratio Outset Medical|ELMD (Electromed) - EV/EBITDA Multiple|LENSAR, Inc (LNSR) - Total Company Value to Operating Income Before Depreciation Ratio|EV/EBITDA Multiple RCEL|Enterprise Value to EBITDA Ratio Profound Medical PROF|EV/EBITDA Multiple BDMD (Baird Medical Investment Holdings)|EV/EBITDA Multiple EDAP TMS S.A. EDAP|APYX - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|ICCM: Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|LUNG (Pulmonx Corp.) - Enterprise Value to EBITDA Ratio|TELA Bio Inc. - Business Value to Operating Income Before Depreciation|CTSO (CytoSorbents Corp) - EV/EBITDA Multiple|Company Value to EBITDA Sensus Healthcare Inc SRTS|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Zynex Medical (ZYXI)|electroCore Medical (ECOR) - Enterprise Value to EBITDA Multiple|Vicarious Surgical Inc - Enterprise Value to EBITDA Ratio|EV/EBITDA Multiple Inspira Technologies Oxy B.H.N. Ltd IINN|IRIDEX Corp - EV/EBITDA Multiple|Total Company Value to Operating Income Before Depreciation Ratio Intelligent Bio Solutions Inc. INBS|Beyond Air (XAIR) - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|Company Value to Operating Income Before Depreciation Ratio PFSA (Profusa, Inc)|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization strataskinsciences.com|Enterprise Value to EBITDA Ratio GlucoTrack, Inc. (GCTK)|EV/EBITDA Multiple NAOV|VERO - Company Value to EBITDA|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Nuwellis, Inc. NUWE|AEMD: Enterprise Value to Operating Income Before Depreciation|ASXC: Enterprise Value to EBITDA Ratio|Avinger, Inc. - Enterprise Value to Operating Income Before Depreciation Ratio|BSGM: EV/EBITDA Multiple|Enterprise Value to EBITDA Ratio Cutera, Inc|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization knowlabs.co|Enterprise Value to Operating Income Before Depreciation NARI (Inari)|Enterprise Value to EBITDA Ratio NVRO (Nevro Corp.)|Total Company Value to Operating Income Before Depreciation Ratio ReShape Lifesciences Inc.|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization silkroadmed.com SILK
